NCI-H2009 Cells

The NCI-H2009 cell line is derived from a human non-small cell lung carcinoma (NSCLC), specifically an adenocarcinoma. This cell line is extensively used in lung cancer research to study the molecular and cellular mechanisms underlying adenocarcinoma, the most common subtype of NSCLC. NCI-H2009 cells are valuable for investigating genetic mutations, signal transduction pathways, and therapeutic responses associated with lung adenocarcinoma.
NCI-H2009 cells exhibit an epithelial morphology and express markers characteristic of lung adenocarcinoma, including cytokeratins and carcinoembryonic antigen (CEA). They harbor genetic alterations frequently observed in NSCLC, such as mutations in the KRAS gene, which is pivotal in cell signaling, growth, and survival. Researchers utilize NCI-H2009 cells to explore key signaling pathways involved in lung cancer progression, such as the EGFR, KRAS, and PI3K/Akt pathways. These cells are also employed in high-throughput drug screening assays and preclinical testing of chemotherapeutic agents, targeted therapies, and immunotherapies. Additionally, NCI-H2009 cells are used to study mechanisms of drug resistance and to develop strategies to overcome it. The relevance of the NCI-H2009 cell line in lung adenocarcinoma research highlights its importance in advancing our understanding of lung cancer biology and in developing new and more effective treatment approaches for patients with NSCLC.